Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNK Stock Summary
- MNK's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.07 -- higher than just 2.04% of US-listed equities with positive expected earnings growth.
- Price to trailing twelve month operating cash flow for MNK is currently 0.13, higher than just 1.85% of US stocks with positive operating cash flow.
- With a price/sales ratio of 0.03, Mallinckrodt plc has a higher such ratio than just 0.86% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Mallinckrodt plc are OSMT, ACOR, IAG, AA, and FTI.
- MNK's SEC filings can be seen here. And to visit Mallinckrodt plc's official web site, go to www.mallinckrodt.com.
MNK Stock Price Chart Interactive Chart >
MNK Price/Volume Stats
|Current price||$0.75||52-week high||$6.42|
|Prev. close||$1.09||52-week low||$0.75|
|Day high||$1.00||Avg. volume||6,488,121|
|50-day MA||$1.36||Dividend yield||N/A|
|200-day MA||$2.79||Market Cap||63.44M|
Mallinckrodt plc Ordinary Shares (MNK) Company Bio
Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.
MNK Latest News Stream
|Loading, please wait...|
MNK Latest Social Stream
View Full MNK Social Stream
Latest MNK News From Around the Web
Below are the latest news stories about Mallinckrodt plc that investors may wish to consider to help them evaluate MNK as an investment opportunity.
A bird in the hand is worth two in the bush. - J. Capgrave "WSJ is controlled by shorties", "This is another trick to trick retail investors to give up their shares" and "#FakeNews". The recent WSJ article has incited vehement comments among stolid Mallinckrodt (MNK) investors, mostly criticizing and...
B. Braun Medical Inc. announces that it has previously settled its Hatch-Waxman litigation brought by Mallinckrodt
BETHLEHEM, Pa., Oct. 2, 2020 /PRNewswire/ -- B. Braun Medical Inc. announces that it has previously settled a patent infringement litigation brought by Mallinckrodt Hospital Products Inc., its affiliates, and New Pharmatop L.P. in response to B. Braun's new drug application (NDA) seeking…
STAT Plus: ‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high
“If you love this country, if you love America, you should be willing to tell Americans that they shouldn't be paying more than the French, and the Germans, and Europeans,”…
Nuclear Medicine/Radiopharmaceutic Market Research With Size, Growth, Key Players, Segments And Forecasts Analysis 2020-2026(Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging)
Los Angeles, United State, – – QY Research recently added a research report, Global Nuclear Medicine/Radiopharmaceutic Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Nuclear Medicine/Radiopharmaceutic market. It highlights the drivers
September proved to be a mixed month as far as drug approvals are concerned, with Mallinckrodt PLC (NYSE: MNK ) and Aquestive Therapeutics Inc (NASDAQ: AQST ) facing rejections. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Among the more fortunate ones were GlaxoSmithKline plc (NYSE: GSK ), which got the nod for an expanded indication - hypereosinophilic syndrome. Bristol-Myers Squibb Co's (NYSE: BMY ) leukemia drug also received FDA's blessings, and after several hiccups, Eton Pharmaceuticals Inc's (NASDAQ: ETON ) out-licensed preservative-free allergic conjunctivitis ophthalmic...
MNK Price Returns